From Elad Katz’s experience

Choosing the clinical gold standard a new diagnostic has to beat

Elad advised biotech and diagnostic ventures on positioning against the clinical gold standard, such as non-invasive biomarkers against biopsy, sharpening go-to-market strategy and target product profiles.

Industry
Health and life sciences
Elad’s role
Advisor

The business need

A new diagnostic or biotech product is judged against the clinical gold standard it aims to displace, for example a non-invasive biomarker test against a biopsy. That comparison shapes the go-to-market strategy, the target product profile and the clinical credibility of the product.

What Elad did

  1. Advised biotech and diagnostic ventures on positioning against the clinical gold standard, for example non-invasive biomarkers against biopsy.
  2. Helped identify the right comparator or gold standard each technology needed to beat.
  3. Sharpened the ventures' go-to-market strategy and target product profiles.
  4. Sharpened the case for the products' clinical credibility.

Decisions this experience speaks to

  • We're comparing our technology to an existing clinical gold standard - is that even the right comparison, and how do we position against it?
  • We have a scientifically impressive platform, but we're not sure it's solving the problem the market actually needs solved - how do we find out?
  • We need to translate complex biological or clinical data into a story that investors, pharma partners, or non-specialist stakeholders will actually understand and back?

Related services and use cases

Sources

  1. Elad Katz’s profile on CTO Grand Rounds